Cell and Gene Outsourcing

  1. Resilience By Design: Lessons From Real-World Disruption 12/2/2025

    Resilience is the bridge to patient access. Discover how to design your logistics with intentional flexibility to withstand real-world disruptions and protect product integrity under pressure.

  2. Why Supply Chain Integration Matters In Advanced Therapy Manufacturing 12/2/2025

    Fragmented supply chains increase risk and delay execution. Integration is key to establish a unified framework that enhances control, reduces administrative burden, and ensures program predictability.

  3. CMC: Accelerate Your Drug Development With A Global Partner 12/2/2025

    With the right Chemistry, Manufacturing & Controls (CMC) consulting services, your organization can excel in early-stage strategizing, accelerate timelines, optimize processes, and reduce costs.

  4. Why Shipping System Qualification Matters In Advanced Therapies 12/2/2025

    Ensuring the integrity of advanced therapies requires documented evidence of robust shipping processes. Qualification is essential for compliance and maintaining continuity across the supply chain.

  5. Built Or Bought? Why Biotechs Are Outsourcing Supply Chain Infrastructure 12/2/2025

    Scaling advanced therapies requires navigating extreme logistics and regulatory hurdles. Learn why moving to a flexible, outsourced model is essential for freeing capital and mitigating global risk.

  6. Optimized Transient Transfection Platform: AAV Program From Gene To GMP 12/2/2025

    Achieve faster AAV gene therapy progress by adopting a unified platform for manufacturing. Accelerate your program to GMP readiness with up to 9x higher titers and robust, high-quality full capsid yields.

  7. Critical Path For Gene Therapy: AAV Analytical Lifecycle Considerations 12/2/2025

    Explore considerations for phase-appropriate AAV characterization and release activities from pre-clinical to late-phase products. Review validation challenges and paths for maturation of analytics.

  8. What's The Greatest Risk For CDMOs Ahead? 12/2/2025

    Economic volatility, regulatory uncertainty, and capacity constraints pose major risks to CDMOs, threatening growth, profitability, and long-term sustainability in an increasingly competitive global market.

  9. New Technology Platforms Being Developed 12/2/2025

    Emerging tools and technology platforms are transforming drug development, enabling faster discovery, improved scalability, and greater precision across biologics, advanced therapies, and data-driven manufacturing processes.

  10. CDMO Trends Impacting 2025-2026 12/2/2025

    Economic pressures, funding shifts, and evolving therapeutic pipelines are reshaping CDMO capacity in 2025, with 2026 expected to bring intensified competition and strategic realignments.